论文部分内容阅读
Background:Therapeutic strategy to activate host innate immunity,like toll-like receptor 7(TLR7) agonist,had a great potential for the treatment of chronic hepatitis B(CHB).Here we investigated the molecular mechanism that contribute to the antiviral response to TLR7 ligand in vitro,as well as the expression of TLR7 in CHB patients and during Peg-IFN-α-2a therapy.